R&D

AbbVie concedes another PhIII cancer drug flop as glioblastoma defeats latest assault

R&D

UPDATED: Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead

Pharma

Under fire for Truvada US pricing at House hearing, Gilead chief O'Day touts R&D costs, asserts governments patents are void
More news caret

calendar Protocols

Quick hits from around the biopharma web

May 17

Takeda receives additional FDA approval for GI drug; Cancer Research UK to test gemcitabine for advanced pancreatic cancer

May 16

AbbVie/Roche's Venclexta wins fourth approval; WuXi, fellow CRO Altasciences ink deal

May 15

IsoPlexis bags $25M to stoke T cell therapy buzz; Collaboration between X4 and LLS; New CMO at Precision Biosciences

May 14

Takeda forecasts $1.7B loss after Shire integration; Flagship's preclinical biotech Axcella closes IPO with $71M+ haul

More Protocols caret

person Peer Review

Weekly biopharma careers news report

May 17

Biogen exec Paul McKenzie heads to CSL as COO; Pulmatrix CEO resigns

May 10

Bicycle signs on new clinical execs in pipeline drive; Howard Stern signs on as FogPharma CSO

May 3

Peer Review: Anil Singhal assumes leadership of Adicet Bio; Adaptive Biotech woos Genentech vet as CMO

Apr 26

Peer Review: Don Hayden commits to CEO role at WindMIL; X4 nabs new CMO Lynne Kelley from Histogenics exile

More peer review caret

Dollar Premium

The top 50 biotechs by market cap — and what their CEOs’ compensation deals tell us about biopharma

The BCMA frenzy: Tracking the 37 drugs around the world racing to overtake bluebird bio and Celgene

Going gangbusters: The top 20 biotech platform deals by upfront cash

Another player in the gene therapy field is gunning for the Duchenne MD crown — and here’s what they're betting on

The top 20 preclinical biotech deals ranked by cash upfront reveals 3 big players — and some major league stinkers

Top 20 cancer drug deals: AstraZeneca just changed the global landscape for dealmaking in oncology

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals

bullhorn Bioregnum

The view from John Carroll

May 14

Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs

May 10

That feeling you get when you hit the finish line, and then set new goals

Apr 17

Ned Sharpless is not playing with the FDA’s gold standard — any more than Scott Gottlieb did

Apr 15

SCOTUS just turned its back on Allergan’s legal maneuver to take a blow at inter partes review. What did you expect?

More opinion caret

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back